GastroEsophageal Cancer New Reference: Nivolumab and Ipilimumab for Advanced Gastric Cancer Ulas D. Bayraktar, MD 2025-09-08
Chronic Lymphocytic Leukemia New Reference: Pirtobrutinib for BTKi Pretreated CLL Ulas D. Bayraktar, MD 2025-09-08
Acute myeloid leukemia New Protocol: Revumenib with Azacitidine and Venetoclax for KMT2-Rearranged / NPM1-Mutated Ulas D. Bayraktar, MD 2025-09-08
Diffuse Large B Cell Lymphoma New Protocol: Glofitamab with R-CHOP for High-Risk DLBCL Ulas D. Bayraktar, MD 2025-09-08
Non-Small Cell Lung Cancer New Indication: Neoadjuvant Osimertinib with/without Chemo for NSCLC Ulas D. Bayraktar, MD 2025-09-08
Hodgkin Lymphoma New Protocol: Brentuximab – ECADD Chemo for Hodgkin Lymphoma Ulas D. Bayraktar, MD 2025-09-08
Pancreatic Cancer New Reference: Advanced Pancreatic Cancer Protocols Ulas D. Bayraktar, MD 2025-09-08
Prostate Cancer New REference: Talazoparib and Enzalutamide for HRR-Deficient Prostate Cancer Ulas D. Bayraktar, MD 2025-09-08
Renal Cell Carcinoma New Indication: Bevacizumab and Erlotinib for Papillary Renal Cell Carcinoma Ulas D. Bayraktar, MD 2025-09-08
Chronic Lymphocytic Leukemia New Reference: MRD-Guided CLL Treatment Ulas D. Bayraktar, MD 2025-09-08
